High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

We discontinued high-dose intravenous immunoglobulin treatment (IVIg) in 7 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who seemed to have responded to IVIg. After discontinuation of treatment, all 7 patients deteriorated. We then randomized the patients to IVIg or placebo...

Full description

Saved in:
Bibliographic Details
Published inNeurology Vol. 40; no. 2; p. 209
Main Authors van Doorn, P A, Brand, A, Strengers, P F, Meulstee, J, Vermeulen, M
Format Journal Article
LanguageEnglish
Published United States 01.02.1990
Subjects
Adult
Child
Chronic Disease
Demyelinating Diseases - physiopathology
Demyelinating Diseases - therapy
Double-Blind Method
Female
Humans
Immunization, Passive
Immunoglobulins - administration & dosage
Infusions, Intravenous
Male
Middle Aged
Neural Conduction
Polyneuropathies - physiopathology
Polyneuropathies - therapy
Polyradiculoneuropathy - physiopathology
Polyradiculoneuropathy - therapy
Randomized Controlled Trials as Topic
Online AccessGet more information

Cover

More Information
Summary:We discontinued high-dose intravenous immunoglobulin treatment (IVIg) in 7 patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who seemed to have responded to IVIg. After discontinuation of treatment, all 7 patients deteriorated. We then randomized the patients to IVIg or placebo (albumin) treatment in a double-blind crossover study. The clinical condition of all patients improved after IVIg and did not improve after placebo treatment. The mean time lapse from the end of the trial treatment to the occurrence of deterioration was 6.4 weeks after treatment with IVIg and 1.3 weeks after treatment with placebo. This selected group of patients with CIDP had a beneficial response to IVIg.
ISSN:0028-3878
DOI:10.1212/wnl.40.2.209